It’s in UK’s interest for Ireland to reach herd immunity
After a disastrous pandemic response that led to one of the worst death rates in the world, the UK’s vaccination programme is finally giving it something to be cheerful about. The UK bought early and broadly, prioritising speed and betting that – although it did not yet know which vaccines would work – at least some would make the cut. These early investments made it possible for vaccine manufacturers to invest in more production capacity early on.
In contrast, the EU was slow, prioritised cost reductions, refused to waive liability for vaccine firms if something went wrong, and focused on a smaller number of vaccines – some of which, like France’s Sanofi vaccines, have suffered setbacks.